Ardelyx (ARDX) Prices 20M Share Upized Offering at $6.25/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Ardelyx (ARDX) Announces Proposed $80M Public Offering of Common Stock
December 4, 2019 4:57 PM ESTArdelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with cardiorenal diseases, today announced that it has commenced an underwritten public offering of up to $80,000,000 of shares of its common stock. All shares of common stock to be sold in the offering will be offered by Ardelyx. In addition,... More
Ardelyx, Inc (ARDX) PT Raised to $10 at SVB Leerink
December 3, 2019 1:14 PM ESTSVB Leerink analyst Ami Fadia raised the price target on Ardelyx, Inc (NASDAQ: ARDX) to $10.00 (from $9.00) while maintaining a Outperform rating.
... MoreArdelyx (ARDX) to Resume Trading at 7:55 am
December 3, 2019 7:37 AM ESTArdelyx (NASDAQ: ARDX) to Resume Trading at 7:55 am
... MoreArdelyx (ARDX) Phase 3 PHREEDOM Study Evaluating Tenapanor in CKD Patients on Dialysis Meets Primary Endpoint
December 3, 2019 7:26 AM ESTArdelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with cardiorenal diseases, today reported positive topline results from PHREEDOM, a long-term Phase 3 study evaluating the efficacy and safety of tenapanor as monotherapy for the treatment of... More
Ardelyx (ARDX) Halted, News Pending
December 3, 2019 7:22 AM ESTArdelyx (NASDAQ: ARDX) Halted, News Pending
... More